Publications by authors named "Claudia Shanley"
Article Synopsis
- POEMS syndrome is a rare condition caused by problems in plasma cells and has five main features: nerve issues, organ enlargement, hormone problems, a specific type of protein in the blood, and skin changes.
- In a study that included 46 patients from Latin America, researchers found that all had nerve problems, and many had skin changes and organ enlargement, with a median time of 7.7 months to get diagnosed.
- The survival rate for patients was really good, with all patients who had a transplant still alive, suggesting that treatment in Latin America is effective and similar to other parts of the world.
Purpose: Multiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce.
Patients And Methods: We analyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MM age 40 years or younger compared with 256 patients age 41-50 years and 957 patients age 51 years or older.
Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from .
Expert Rev Hematol
March 2021
Objectives: We compared the efficacy of lenalidomide-dexamethasone (Rd) based treatments for relapsed/refractory multiple myeloma patients (pts), in a real-world setting. In addition, we evaluated adverse events (AE), progression-free survival (PFS) and overall survival (OS).
Methods: In our retrospective, multicentric study, 156 pts with RRMM were included.
Article Synopsis
- The study examined the clinical and survival characteristics of transplant-eligible multiple myeloma patients in Latin America, focusing on the differences between public and private healthcare systems.
- It included data from 1293 patients diagnosed from 2010 to 2018, highlighting significant disparities in outcomes and survival rates between those treated in public versus private institutions.
- The findings suggest that late diagnosis and limited access to effective treatments in public facilities contribute to poorer survival rates, while patients receiving modern therapies and autologous stem cell transplants have survival rates comparable to international standards.
Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multiple myeloma patients.
View Article and Find Full Text PDFBackground: Monoclonal gammopathy of renal significance (MGRS)-related lesions are infrequent entities. There are no publications on these disorders in Latin America (LA). The aim of this study was to describe epidemiological and clinical characteristics of these patients in LA.
View Article and Find Full Text PDFMultiple myeloma is a hematologic disease, which accounts for 15% of hematologic malignancies. The average age of onset is between 65-70 years and is very rare in young patients, as 2% are under 40 years old. We present a case of 36-year-old women with history of 20 pack years (p/y) smoking, who complaints of dyspnea associated with signs of right cardiac overload, anemia, proteinuria, elevated acute phase reactants and spirometry pattern suggestive of moderately-severe restriction and severe drop in diffusing capacity for carbon monoxide (DLCO).
View Article and Find Full Text PDFArticle Synopsis
- A case is presented of a patient with multiple myeloma and giant cell arteritis, highlighting a novel occurrence without the presence of systemic amyloidosis.
- This instance is significant as it marks the first documented case of its kind in medical literature.
- The findings suggest a potential pathogenic relationship between multiple myeloma and giant cell arteritis, warranting further investigation.
ABO incompatibility in allogeneic bone marrow transplantation may be associated with incomplete or delayed erythroid engraftment, being pure red cell aplasia (PRCA) the most severe complication in this setting. Attempts for the treatment of PRCA have been made with erythropoietin or with plasmapheresis with relative success, and some authors have reported the reversibility of PRCA with antilymphocyte globulin (ALG or ATG), based on the assumption that PRCA might be immunologically mediated. We report herewith a patient with acute leukemia who developed post--BMT pure red cell aplasia.
View Article and Find Full Text PDF